16TH INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

16-17 OCTOBER 2009, THE QUEEN ELIZABETH II CONFERENCE CENTRE, LONDON, UK

Delegate Book
Front cover image: Churchill Statue and Big Ben, London.
Dear Colleagues,

The annual International Symposium on Thromboembolism presents clinicians with a prime opportunity to update themselves on the latest developments in thromboembolism.

Organised by the Thrombosis Research Institute, and now in its 16th year, the meeting is once again bringing together globally recognised leaders and experts from the rapidly developing field of thromboembolism. We are delighted to be in London for what promises to be a most informative and rewarding conference.

As you will see from the enclosed programme, highlights of the meeting include a stimulating range of in-depth plenary sessions covering the challenges of venous thromboembolism, cancer-associated thrombosis and arterial disease, as well as interactive workshops and ‘meet the expert’ sessions. These more intimate sessions with our esteemed Faculty are a unique opportunity, and will give us the chance to explore many topics ranging from difficult clinical situations to novel antithrombotic agents.

I hope that the excellent scientific programme and the remarkable historical surroundings here in Westminster will ensure that you enjoy your time with us in London.

With best wishes,

Professor Ajay K Kakkar
Chairman
**Day One**  
**Friday 16 October 2009**

**Guide to Meeting Rooms**
- Mountbatten Room: 6th floor
- Mountbatten Lounge: 5th floor
- Henry Moore, Rutherford and Wesley Rooms: 4th floor
- Guild Room: 3rd floor mezzanine

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.45 – 14.00</td>
<td>Lunch</td>
<td>Mountbatten Lounge</td>
</tr>
<tr>
<td>14.00 – 14.05</td>
<td>Welcome</td>
<td>Mountbatten Room</td>
</tr>
<tr>
<td></td>
<td>A.K. Kakkar, UK</td>
<td></td>
</tr>
<tr>
<td>14.05 – 15.30</td>
<td>Plenary Session I</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Challenges in Venous Thromboembolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Chairmen: V.V. Kakkar, UK; G. Agnelli, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prevention of VTE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A.G.G. Turpie, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment of VTE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P. Prandoni, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Update on pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R. Hull, Canada</td>
<td></td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td>Coffee</td>
<td>Mountbatten Lounge</td>
</tr>
<tr>
<td>16.00 – 17.30</td>
<td>Plenary Session II</td>
<td>Mountbatten Room</td>
</tr>
<tr>
<td></td>
<td>Cancer-Associated Thrombosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Chairmen: H. Büller, The Netherlands; M. Levine, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Who is at risk?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Francis, USA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prevention of cancer-associated thrombosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>G. Agnelli, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antithrombotic therapy – biological implications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A.K. Kakkar, UK</td>
<td></td>
</tr>
</tbody>
</table>
### Day Two  
**Saturday 17 October 2008**

**09.00 – 10.00**  
**Meet the Expert Sessions**

1. **Novel antithrombotic agents**  
   – will they change my practice?  
   **Henry Moore**  
   *H. Bounaumeaux, Switzerland*

2. **Laboratory haemostasis – what is new?**  
   **Guild**  
   *A. Falanga, Italy*

3. **Clinical trials in VTE – what is relevant?**  
   **Rutherford**  
   *C. M. Samama, France*

4. **Biosimilar heparins**  
   **Wesley**  
   *J. Harenberg, Germany*

**10.00 – 10.15**  
**Coffee**  
*Mountbatten Lounge*

**10.15 – 12.45**  
**Workshops**

**1. Difficult Clinical Situations**  
**Henry Moore**

*Co-Chairmen:*
*H. Bounaumeaux, Switzerland; V.V. Kakkar, UK*

1. The obese patient  
   **S. Haas, Germany**

2. Renal impairment  
   **R. Bauersachs, Germany**

3. Pregnancy  
   **P. Prandoni, Italy**

**2. Atrial Fibrillation**  
**Wesley**

*Co-Chairmen:*
*R. Hull, Canada; J. Shepherd, Scotland*

1. What is the role of anti-platelet therapy?  
   **A.G.G. Turpie, Canada**

2. Modifying risk factors to improve outcomes  
   – what is the evidence?  
   **G.Y.H. Lip, UK**

**3. Cancer**  
**Rutherford**

*Co-Chairmen:*
*A. Falanga, Italy; M.M. Samama, France*

1. Incidental pulmonary embolism should be treated  
   **Yes:**  
   *A. Falanga, Italy*  
   **No:**  
   *C. Francis, USA*

2. Chemotherapy patients should receive routine thromboprophylaxis  
   **Yes:**  
   *C. Kessler, USA*  
   **No:**  
   *M. Levine, Canada*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.45 – 14.00</td>
<td>Lunch</td>
<td>Mountbatten Lounge</td>
</tr>
<tr>
<td>14.00 – 15.30</td>
<td>Plenary Session III</td>
<td>Mountbatten Room</td>
</tr>
<tr>
<td><strong>Arterial Disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chairmen: S. Haas, Germany; A.G.G. Turpie, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antithrombotic therapy for secondary prevention of coronary artery disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>F. Verheugt, The Netherlands</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation – what is new, what can we expect?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>G.Y.H. Lip, UK</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>How should we use statins in 2009?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>J. Shepherd, Scotland</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30 – 16.15</td>
<td>Debate</td>
<td></td>
</tr>
<tr>
<td><strong>Should low-molecular-weight heparins be given to all cancer patients to prolong survival?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chairman: A.K. Kakkar, UK</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Yes:</strong></td>
<td><em>H. Büller, The Netherlands</em></td>
<td></td>
</tr>
<tr>
<td><strong>No:</strong></td>
<td><em>M. Levine, Canada</em></td>
<td></td>
</tr>
<tr>
<td>16.15 – 16.30</td>
<td>Closing Remarks</td>
<td></td>
</tr>
<tr>
<td><em>S. Haas, Germany</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Sylvia Haas, MD, is an emeritus Professor of Medicine and had been Director of the Haemostasis and Thrombosis Research Group at the Institute for Experimental Oncology and Therapy Research, Technical University of Munich, Germany, for almost 30 years. Professor Haas received her medical degree from the University of Freiburg and began her training in paediatric haematology and oncology at the Dr. von Haunersches Kinderspital, University of Munich. She continued her training in internal medicine at the Technical University in Munich and received full professorship after having established the Haemostasis and Thrombosis Research group at the Institute for Experimental Surgery, now the Institute for Experimental Oncology and Therapy Research.

Professor Haas’s scientific focus is on the development of new antithrombotic therapies, laboratory monitoring of anticoagulants, biomarkers and tumour-associated thrombosis. Professor Haas is involved in several clinical trials, in particular trials in prevention and treatment of arterial and venous thromboembolism. She is also in charge of various integrated teaching programmes.

Professor Haas is a member of several professional societies, including the International Society on Thrombosis and Haemostasis (ISTH), the International Society of Angiology, the European Society for Surgical Research (ESSR), and the German Societies of Surgery, Angiology, and Thrombosis and Haemostasis Research. She is a fellow of the Southern African Society of Thrombosis and Haemostasis (SATH) and is also a member of the editorial board for peer-reviewed journals, including Current Hematology Reports, International Angiology, and Clinical and Applied Thrombosis/Hemostasis.
Ajay Kakkar

Barts and the London School of Medicine and Dentistry, Queen Mary College, University of London, London, UK

Ajay Kakkar, MBBS (Hons), BSc, PhD, FRCS, is Professor of Surgical Sciences and Dean for External Relations, Barts and the London School of Medicine and Dentistry, Queen Mary College, University of London; Consultant Surgeon, St. Bartholomew’s and University College London Hospitals; and Director of the Thrombosis Research Institute, London, UK. Professor Kakkar received his medical education at King's College Hospital Medical School, University of London, and was awarded a MBBS in 1988 and a PhD in 1998. He was made a Fellow of the Royal College of Surgeons of England in 1992.

His awards include Hunterian Professor, Royal College of Surgeons of England 1996, the David Patey Prize, Surgical Research Society of Great Britain and Ireland 1996, the Knoll William Harvey Prize, International Society on Thrombosis and Haemostasis 1997, and the James IV Association of Surgeons Fellow 2006.

Professor Kakkar's research interests are in the prevention and treatment of venous thromboembolic disease and cancer-associated thrombosis.
Vijay Kakkar
Thrombosis Research Institute, London, UK and Thrombosis Research Institute, Bangalore, India

Vijay Kakkar, FRCS, FRCSE, Hon DSc, is Emeritus Professor at the University of London, UK, and Founder-President of the Thrombosis Research Institute (TRI), London, and Founder-Chairman of the Thrombosis Research Institute, Bangalore, India.

Professor Kakkar graduated from Vikram University, Ujjain, India, in 1960 and qualified as Fellow of the Royal College of Surgeons of Edinburgh and England in 1964.

Professor Kakkar has held a number of appointments at King’s College, University of London. He has been the recipient of a number of distinctions and awards, including a Hunterian Professorship from the Royal College of Surgeons, Visiting Professor of Harvard University, Honourable Fellowship of the Association of Surgeons of India, a lifetime achievement award from the Union of Angiology, and most recently, an Honorary Doctor of Science from the Loyola University of Chicago. He is a member of a number of professional societies and was a founding member of the British Society of Haemostasis and Thrombosis (BSHT). His publications include over 650 original articles, six books, and contributions to 50 texts.

In 1989, Professor Kakkar established the TRI as a national resource to provide a multidisciplinary environment dedicated to the study of thrombosis and related disorders.
Mark Levine

McMaster University, Hamilton, Ontario, Canada

Mark Levine is Chair and Professor in the Department of Oncology at McMaster University, Hamilton, Ontario, Canada. He holds the Buffett Taylor Chair in Breast Cancer Research at McMaster University. He is a past recipient of the O. Harold Warwick Prize (1999) from the National Cancer Institute of Canada. Dr Levine received his medical degree from McGill University, Montreal, Quebec, Canada, and completed his residency in internal medicine at McMaster University. He completed his training in haematology and oncology at Duke University Medical Center, Durham, North Carolina, USA. In addition, Dr Levine received a master’s degree in clinical epidemiology and biostatistics from McMaster University.

In 1982, Dr Levine became a member of both the Faculty of Health Sciences at McMaster University, and a medical oncologist at the Hamilton Regional Cancer Center (now known as the Juravinski Cancer Center – Hamilton Health Sciences). He was CEO of the Cancer Centre between 1992 and 1999. Over the past 27 years he has been an active researcher in clinical trials and health services research. His focus is in the areas of breast cancer and venous thromboembolism. A number of the trials he has conducted have impacted on health care in both Canada and internationally. He helped establish the Ontario Clinical Oncology Group (OCOG) in 1982 and is now the Director. OCOG designs, coordinates and analyses multicentre trials in cancer. Dr Levine has over 230 publications in peer-reviewed journals and has brought much research funding to McMaster. He was Chairman of Health Canada’s Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Dr Levine was an Associate Editor of the Journal of Clinical Oncology for seven years and now is a Consultant Editor.
Giancarlo Agnelli

*University of Perugia, Perugia, Italy*

Giancarlo Agnelli, MD, is Professor of Internal Medicine at the University of Perugia, Italy, and Director of the Department of Internal and Cardiovascular Medicine and Stroke-Unit at the University Hospital in Perugia, Italy.

Professor Agnelli received his medical degree from the University of Perugia. He was a Research and Clinical Fellow at the Department of Medicine, McMaster University, Hamilton, Ontario, Canada, and at the Academic Medical Centre, University of Amsterdam, The Netherlands.

Professor Agnelli was a member of the Conference on Antithrombotic and Thrombolytic Treatment of the American College of Chest Physicians (ACCP) 4th to 8th editions.

He is a member of the Editorial Board of *Thrombosis Research, Haemostasis, Journal of Cardiovascular Medicine, Acta Cardiologica,* and *Trends in Medicine.* Professor Agnelli also is a reviewer for the *New England Journal of Medicine, The Lancet, Circulation, Blood, Cardiovascular Research, Journal of Thrombosis and Haemostasis* and the *Journal of the American College of Cardiology.*

He has authored more than 300 publications in peer-reviewed international journals.
Rupert Bauersachs, MD, is Professor of Internal Medicine, Director of the Max-Ratschow Klinik for Vascular Medicine at the Klinikum Darmstadt, and Head of the Vascular Centre Darmstadt. Professor Bauersachs received his medical degree from the University of Munich. He was a Postdoctoral Fellow at the Department of Pharmacology, University of Munich and subsequently a Research Fellow of the American Heart Association at the Department of Physiology at the University of Southern California.

Professor Bauersachs completed his residency in internal medicine at the München-Bogenhausen Hospital and the Universities of Mainz and Frankfurt. He has been certified for Internal Medicine, Vascular Medicine, Haemostaseology, Diabetology, Phlebology, Aviation Medicine and he is Fellow and National Delegate of the International Union of Angiology.

In 1999, he became a faculty member of the University of Frankfurt and Head of the Department of Vascular Medicine. He was one of the founding members of the first German University Vascular Centre. In 2003, he was appointed Director of the Max-Ratschow Klinik for Vascular Medicine. Professor Bauersachs is a council member for the German Societies of Angiology and Microcirculation and is active in various other societies for Vascular Medicine and Thrombosis and Haemostasis. His interests are venous thromboembolism (VTE), thrombophilia, antithrombotic agents and women’s issues in thrombosis. He has published more than 50 original papers, and his scientific work has been awarded several prizes.
Henri Bounameaux graduated as MD in Basle, Switzerland in 1978. Board certified in internal medicine and vascular medicine, he became Director of the Division of Angiology and Haemostasis at the University Hospitals of Geneva in 1993. Since 2002, he has been Professor of Medicine at the University of Geneva and Chairman of the Department of Medicine.

Professor Bounameaux’s research interests cover all aspects of venous thromboembolism (VTE). He has authored 300 papers in peer-reviewed journals and 100 reviews, didactic papers and book chapters. He serves as a reviewer for some of the most important journals in the fields of internal and vascular medicine.

Professor Bounameaux has received many awards including the Karl Rohr Prize of the Swiss Society of Haematology (1991), the Award of the Swiss Society of Angiology (1991), the Theodor Naegeli International Thrombosis Award (1995), an Investigator Recognition Award (2003) and a Distinguished Career Award (2009) from the International Society on Thrombosis and Haemostasis (ISTH). He serves on the Data Safety Monitoring and Steering Committees of several international diagnostic and therapeutic trials on VTE.

He was the President of the 2007 ISTH World Congress in 2007 in Geneva and is currently Chairman Elect of ISTH Council.
Harry Büller, MD, is Professor of Internal Medicine, specialising in Vascular Medicine at the Academic Medical Centre in Amsterdam, Holland.

Professor Büller earned his MD and PhD at the University of Amsterdam. After graduating, he completed his research fellowship in haemostasis and thrombosis in the Departments of Medicine and Clinical Epidemiology and Biostatistics at McMaster University in Hamilton, Ontario, Canada.

Professor Büller has authored and co-authored more than 500 scientific articles concerning topics in his field. He has been Co-Chairman for the Amsterdam Institute for Cardiovascular Research and is Chairman of the Vascular Medicine Working Group. He is a reviewer for The New England Journal of Medicine, The Lancet, Archives of Internal Medicine, and European Journal of Clinical Investigation, among others. He is a member of the editorial Board of The Annals of Internal Medicine.

Professor Büller was Chairman of the 2004 CHEST conference on antithrombotic therapy for venous thromboembolic disease: the Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy. He is the recipient of the Established Investigator Award presented by the Dutch Heart Foundation and received the Dutch Society for Vascular Medicine 2005 Award. Since 2008 he has served as Honorary Professor of the Royal Netherlands Academy of Arts and Sciences.
Anna Falanga

University of Milan-Bicocca, Milan, Italy

Anna Falanga is the Head of the Division of Immunohaematology/Tranfusion Medicine and the Haemostasis and Thrombosis Centre, at the Department of Oncology-Haematology, Ospedali Riuniti in Bergamo, Italy, as well as being Professor of Haematology at the University of Milan-Bicocca.

Having received her medical degree and board certification in internal medicine at the University of Naples, Dr Falanga obtained her board certification in haematology at the University of Verona, Italy. Subsequently, she spent three years working as a postdoctoral fellow in the Matio Negri Institute in Milan, Italy, and a further two years at the University of Colorado’s School of Medicine in Denver, USA.

Dr Falanga’s research interests include the study of the interactions of malignant cells with the haemostatic system, the role of antithrombotic agents in human cancer and experimental models, and the management of venous thromboembolism (VTE) in cancer patients.

Dr Falanga became an elected member of the Scientific and Standardization Committee’s (SSC) of the International Society of Thrombosis and Haemostasis (ISTH), in 2002, and was Chairman of the sub-committee on Haemostasis and Malignancy from 2002 to 2006. She is currently Chairman Elect of the ISTH SSC. She has an active role in many professional societies, for example, she is a member of the committee on Haemostasis of the American Society of Haematology (ASH) and is a member of the Council of the European Haematology Association (EHA). Dr Falanga is also the Vice-President of the Italian section of the Medical Women International Association (MWIA).
Charles Francis, MD, is Professor of Medicine and of Pathology and Laboratory Medicine at the University of Rochester. He obtained his MD degree at the University of Pittsburgh and was then an Intern and Resident in Medicine at the University of North Carolina. He joined the University of Rochester as a Fellow in Haematology in 1976, and he has remained at that institution where he is the Director of the Haemostasis and Thrombosis programme.

Dr Francis has been the recipient of a Clinical Investigator Award from the National Heart, Lung and Blood Institute (NHLBI) and an Established Investigator Award from the American Heart Association (AHA). He has served on numerous National Institutes of Health (NIH) review and advisory committees. He is a past Chairman of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH) and Programme Chairman of the XVIIth International Congress on Haemostasis and Thrombosis. He serves as the Editor in Chief of *Thrombosis Research*.

Dr Francis has both clinical and laboratory research interests. Laboratory research has focused on the structure of fibrinogen and fibrin and mechanisms of fibrinolysis. Current work relates to the work of fibrinogen and fibrin in modulating the effects of FGF-2 on endothelial cells. His clinical research has been in the areas of venous thrombosis and new anticoagulants.
Job Harenberg

University of Heidelberg, Heidelberg, Germany

Job Harenberg is Professor of Medicine and Haemostaseology in the Department of Clinical Pharmacology, Mannheim, University of Heidelberg. He has worked for more than thirty years in thrombosis and haemostasis research and in the clinical treatment of patients.

Professor Harenberg has several patents on new anticoagulants for diagnostic purposes and he has published more than 200 peer-reviewed papers. He specialises in new antithrombotic agents for use in conventional and new indications. This year, he organised the 17th Glycosaminoglycan Symposium with Dr Benito Casu close to Lake Como in Northern Italy.
Russell Hull

Foothills Medical Centre and University of Calgary, Calgary, Canada

Russell Hull, MBBS, MSc, FRCPC, FACP, FCCP, is a Professor of Medicine for the Departments of Medicine and Community Health Sciences, as well as the Director of the Thrombosis Research Unit, Calgary, Alberta, Canada.

He received his Medical Degree in Medicine and Surgery at the University of Sydney, Australia. He received his Master of Science in Clinical Epidemiology from McMaster University, Canada.

Dr Hull is a fellow of the Royal Australasian College of Physicians (RACP), Royal College of Physicians and Surgeons of Canada (RCPSC), American College of Chest Physicians (ACCP) and American College of Physicians (ACP). He is a member of the Canadian Medical Association (CMA) and International Society on Thrombosis and Haemostasis (ISTH). Dr Hull is Editor in Chief of the Clinical and Applied Thrombosis and Haemostasis (CATH) Journal. He also currently serves on the editorial boards of three other journals. His publications include over 800 original articles. He has served as the Principal Investigator for numerous trials and is an author of the 2006 International Consensus Statement for the Prevention and Treatment of Venous Thromboembolism.

Dr Hull has received a number of awards and distinctions for his contributions towards improving care for patients with thrombosis, including among others: the Jobst Lectureship of the University of Michigan; the Nina W. Werblow Lectureship of the Medical College of Cornell University; I. Jerome Flance Lectureship of the Washington University School of Medicine; the William Cohen/Stella Fisher Lectureship; The Lancet Bookshelf Section in 1996; the Coupland Lectureship of the Royal North Shore Hospital; the Investigator Recognition Award of the ISTH; the College Medalist Award Lecturer of the ACCP and the Distinguished Scientist Award of the Canadian Society for Clinical Investigation.
Craig M Kessler

Georgetown University Medical Centre and
the Lombardi Comprehensive Cancer Centre,
Washington DC, USA

Craig M Kessler, MD, received his medical degree from the Tulane University School of Medicine in New Orleans, Louisiana, where he was a member of Alpha Omega Alpha Honor Society. He completed his residency in Internal Medicine at the Ochsner Foundation Hospital and his fellowship in Haematology/Oncology at the Johns Hopkins Hospital and University in Baltimore, Maryland.

Dr Kessler then became a full-time Faculty Member and Attending Physician in the Section of Special Haematology at the National Institute of Health in Bethesda, MD. In 1982, he joined the Division of Haematology and Oncology at the George Washington University School of Medicine where he rose to the rank of tenured Professor of Medicine and Chief of the Division. He is currently Professor of Medicine and Pathology at the Georgetown University Medical Centre and the Lombardi Comprehensive Cancer Centre where he is the immediate past Chief of the Division of Haematology/Oncology, is currently Director of the Division of Coagulation, Director of Cellular and Therapeutic Apheresis, and Director of the Haemophilia and Thrombophilia Comprehensive Treatment Centre.

Dr Kessler is Co-Editor of *Haemophilia* and *Seminars in Thrombosis and Hemostasis*, and is the Chairman of the Medical and Scientific Council of the National Hemophilia Foundation. He has also been awarded Mastership in the American College of Physicians. He has published 175 peer reviewed articles and four books.
Gregory Y H Lip

City Hospital, Birmingham, UK

Gregory Lip is Professor of Cardiovascular Medicine at the University of Birmingham and Visiting Professor of Haemostasis Thrombosis and Vascular Sciences, University of Aston in Birmingham. In addition, he is Director of the Haemostasis Thrombosis and Vascular Biology Unit in the Centre for Cardiovascular Sciences at City Hospital, Birmingham.

Professor Lip’s present appointment allows full clinical responsibilities in cardiovascular medicine (including invasive and noninvasive cardiology), as well as teaching and cardiovascular research. His research interests are in atrial fibrillation (AF), hypertension, heart failure, thrombosis and antithrombotic therapy and ethnic differences in vascular disease. Finally, he leads a large laboratory-based research group in thrombosis and vascular biology in cardiovascular disease and stroke.

Professor Lip was Clinical Adviser to the guideline development group that wrote the UK National Institute for Health and Clinical Excellence (NICE) guidelines on the management of AF. He is co-author of the American College of Chest Physicians (ACCP) Consensus Guidelines on Antithrombotic Therapy for AF. He has also been involved in local epidemiological surveys of thromboprophylaxis for AF and formulation of regional/national antithrombotic therapy guidelines for AF.

Professor Lip was involved in the Birmingham Atrial Fibrillation Treatment in the Aged (BAFTA) clinical trial, comparing aspirin and warfarin in elderly (aged > 75) patients with AF in the primary care setting. He is currently Chairman of steering committees for Phase 2 and Phase 3 clinical trials on stroke prevention in AF and has served on Clinical Events Committees or Data Safety Monitoring Boards for clinical trials in AF.

Professor Lip has published and lectured extensively on the clinical epidemiology of AF, as well as on the pathophysiology of thrombosis in cardiovascular disease.
Paolo Prandoni

Institute of Medical Semeiotics, University of Padua, Padua, Italy

Paolo Prandoni, PhD, is Professor at the Department of Medical and Surgical Sciences, Thromboembolism Unit, at the University of Padua. He trained at the University of Padua from 1971-79 before moving to Holland where he studied for his PhD at the University of Amsterdam in 1992.

Professor Prandoni’s research and professional experiences cover epidemiology, diagnosis and management of thromboembolism. Of particular interest to him are studies addressing cancer-associated venous thromboembolism (VTE).

Key achievements include; the demonstration of the value of real-time compression ultrasonography for the diagnosis of deep vein thrombosis (DVT); the confirmation of the risk for subsequent overt cancer in patients with idiopathic VTE; the demonstration that low-molecular-weight heparins (LMWHs) are as effective and safe as unfractionated heparin (UFH) in the treatment of DVT; the demonstration that LMWHs allow the home treatment of DVT; the description of the natural history of DVT, outlining the particularly high risk of recurrent thromboembolism in cancer patients; the demonstration that both Factor V Leiden and G20210A prothrombin variant are independent risk factors for recurrent VTE; the demonstration that residual vein thrombosis is a predictive marker of recurrent thromboembolism; the demonstration that cancer patients with venous thrombosis have a high risk of recurrent thromboembolism while on anticoagulation; the demonstration of an association between atherosclerosis and venous thrombosis; the demonstration that chronic pulmonary thromboembolic hypertension following an episode of pulmonary embolism is more frequent than commonly thought.

Professor Prandoni has published more than 300 papers in peer-review journals.
Charles Marc Samama is Professor and Chairman in the Department of Anaesthesiology and Intensive Care of the Hôtel-Dieu University Hospital in Paris, France. He is board certified to practice anaesthesiology and intensive care medicine.

Professor Samama holds a master’s degree in Haemostasis and Thrombosis and his PhD dissertation was based on an experimental model of thrombosis in the pig. He is head of a laboratory in the INSERM 765 research unit and for many years has developed an experimental model of arterial thrombosis and bleeding in the rabbit.

Professor Samama is the past president of the Scientific Committee of the French Society of Anaesthesiology and Intensive Care (SFAR). He has been elected to the Board of Directors of the European Society of Anaesthesiologists (ESA) and is also a member of the International Society on Thrombosis and Haemostasis (ISTH).

Professor Samama serves as a consultant for a number of professional journals in anaesthesiology, haemostasis and drug safety, and has published more than 120 peer-reviewed articles and anaesthesiology reviews. He is directing the second edition of the French Guidelines on Perioperative Venous Thromboembolism (VTE) Prophylaxis. He has co-authored the VTE prophylaxis section of the 8th ACCP Guidelines, and he has been selected as a panelist for the forthcoming 9th edition.
Meyer-Michel Samama

Hôtel-Dieu University Hospital, Paris, France

Meyer-Michel Samama, MD, is Professor Emeritus of Haematology at Hôtel-Dieu University Hospital, Faculty of Medicine, where he was formerly Chairman of the Department of Haematology and Scientific Adviser and Delegate Director at Biomnis Laboratory. He qualified as a pharmacist-pathologist, then as a medical doctor and then as Professor of Haematology from the Paris VI University School of Medicine. His study on venous thromboembolism prophylaxis in medical patients (medenox study) was selected to be presented at the Presidential Symposium of the International Society on Thrombosis and Haemostasis (ISTH) in 1999 and is a frequently quoted work published in *New England Journal of Medicine*. Professor Samama was elected corresponding member of the National Academy of Pharmacy in 2001. He has presented three lectures at the National Academy of Medicine.

Professor Samama’s research interests centre on haemostasis and pathogenesis of venous thrombosis. Current fields of focus include the diagnosis and treatment of hereditary thrombophilia and the pharmacology of antithrombotic drugs including low-molecular-weight heparins, fondaparinux and new antithrombotic agents. He has published more than 400 original articles and has co-edited a number of books on clinical thrombosis and hypercoagulable states.

He received a Distinguished Career Award for his contributions to haemostasis from the ISTH. He also received an award from the International Society of Fibrinolysis and Thrombolysis and from the Venous Thrombosis Forum for his contribution to the field. He is a member of the Editorial Board of the *Journal of Thrombosis and Haemostasis* and he is a member of the American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. He sits on the review board of several journals and is a member of several professional societies.
James Shepherd, MB ChB, PhD, has been Professor and Head of the Department of Vascular Biochemistry and Honorary Consultant at the University of Glasgow Royal Infirmary, Glasgow, Scotland, since 1988.

Professor Shepherd is a Fellow of the Royal College of Pathologists of London, the Royal College of Physicians and Surgeons of Glasgow, the Academy of Medical Sciences and the Royal Society of Edinburgh.

Professor Shepherd has spent periods researching abroad at Baylor College of Medicine, Texas; the Cantonal Hospital, Geneva and the University of Helsinki and is former Chairman of the European Atherosclerosis Society (EAS) and Founder-member of the British Hyperlipidaemia Association and the Asian Pacific Society of Atherosclerosis and Vascular Disease (APSAVD).

Professor Shepherd's research is directed towards understanding those factors which are responsible for the development of coronary artery disease. In particular, he has focused on the roles played by heredity and environment in the regulation of the levels of fats (like cholesterol) in the blood. He directed the West of Scotland Coronary Prevention Study (WOSCOPS) and presented its findings at the American Heart Association (AHA) meeting in November 1995. In November 2002 he presented the results of the Prospective Study of the Pravastatin in the Elderly at Risk (PROSPER) Study to the AHA in Chicago. This study was conducted in three countries, The Netherlands, Ireland and the United Kingdom and investigated the benefits of cholesterol lowering in the elderly at risk. His current research activities focus on the Treating to New Targets study (TNT) and JUPITER (A Randomized, Double-Blind, Placebo Controlled, Multi Centre, Phase III Study of Rosuvastatin 20mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein).
Alexander G G Turpie

*McMaster University, Hamilton, Ontario, Canada*

Alexander Turpie, MD, is Professor of Medicine at McMaster University and an internist on the staff of Hamilton Health Sciences, Hamilton, Ontario, Canada. Professor Turpie received his medical degree from the University of Glasgow, Scotland. After completing a residency at the Glasgow Royal Infirmary and a residency and clinical research fellowship at Stobhill General Hospital, Glasgow, he was a clinical lecturer at the University of East Africa Medical School, Nairobi, Kenya. After returning to the University of Glasgow for additional training in haemostasis and thrombosis, Professor Turpie was appointed MRC Fellow in Pathology at McMaster University in 1970, and joined the Faculty in the Department of Medicine there in 1972.

Professor Turpie has published over 700 articles, abstracts, book chapters and books, and is a reviewer for several journals, including *Annals of Internal Medicine, Circulation, The Lancet,* and the *New England Journal of Medicine.*

Professor Turpie’s research interests include new antithrombotic drugs for the management of venous and arterial thrombosis and anticoagulant therapy in patients with prosthetic heart valves. He has served on numerous professional and university-related committees and is a frequent lecturer at professional meetings worldwide. Professor Turpie also serves on the editorial boards of *Vascular Medicine Review* and *HeartDrug.*
Freek Verheugt

University Hospital, Nijmegen, The Netherlands

Freek Verheugt MD, FESC, FACC, FAHA is Professor of Cardiology at the Heart-Lung Centre of the University Medical Centre of Nijmegen and Chairman of the Department of Cardiology, Onze Lieve Vrouwe Gasthuis in Amsterdam, The Netherlands.

Professor Verheugt graduated from the University of Amsterdam in 1974 and wrote a thesis on platelet and granulocyte antigens and antibodies. He trained in cardiology at the Thoraxcenter of the Erasmus University in Rotterdam. He has been a Professor at the University of Colorado Health Sciences Centre in Denver, USA, and at the Free University in Amsterdam. He was President of the Netherlands Society of Cardiology between 1999 and 2001.

Professor Verheugt has published over 370 papers in peer-reviewed international journals including New England Journal of Medicine, The Lancet, Circulation, Journal of the American College of Cardiology and European Heart Journal, of which is an Editorial Board Member. He is an editorial adviser of The Lancet and Circulation. He has over 10,000 citations. His main fields of scientific interest are pharmacological and interventional treatments of acute coronary syndromes.
Organised under the auspices of the Thrombosis Research Institute, London, United Kingdom and supported by an unrestricted educational grant from Bristol-Myers Squibb, Eisai, Pfizer and sanofi-aventis.